Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
J Periodontal Res ; 45(5): 664-71, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20572921

ABSTRACT

BACKGROUND AND OBJECTIVE: Purine nucleoside phosphorylase (PNP) is an enzyme that catalyzes the reversible phosphorolysis of purine nucleosides, playing a key role in the purine salvage pathway. Activated T cells seem to rely heavily on PNP to remain functionally active and are particularly sensitive to PNP deficiency. The role of PNP in periodontal tissues has not been characterized thus far. The aim of this study therefore was to assess the activity and expression of PNP in the gingival tissues of periodontitis patients. MATERIAL AND METHODS: Ten patients consecutively admitted for treatment had their periodontal clinical variables recorded and their gingival crevicular fluid collected. After periodontal treatment the patients were seen once a month for plaque and bleeding control, and had their periodontal variables recorded and gingival crevicular fluid collected at 90 and 180 d. Purine nucleoside phosphorylase-specific activity was assessed using a spectrophotometer through the addition of the PNP substrate analog 2-amino-6mercapto-7-methyl purine riboside to the gingival crevicular fluid. In parallel, PNP expression was assessed by immunohistochemistry and real-time PCR in gingival biopsies and cell culture. RESULTS: Purine nucleoside phosphorylase activity was higher in the gingival crevicular fluid of periodontally diseased sites, which was positively correlated with improvements of the clinical variables. Treatment of periodontal disease induced a striking decrease of PNP activity in periodontally diseased sites. Expression of PNP was more pronounced in mononuclear cells and endothelial cells of the gingiva, and the mRNA levels were 5.7-fold higher in inflamed tissues compared with control samples. CONCLUSION: Purine nucleoside phosphorylase activity and expression are upregulated in periodontally diseased sites and can be detected in the gingival crevicular fluid.


Subject(s)
Aggressive Periodontitis/enzymology , Chronic Periodontitis/enzymology , Gingival Crevicular Fluid/enzymology , Purine-Nucleoside Phosphorylase/genetics , Purine-Nucleoside Phosphorylase/metabolism , Adult , Aged , Aggressive Periodontitis/therapy , CD4-Positive T-Lymphocytes/enzymology , Chronic Periodontitis/therapy , Gene Expression Regulation, Enzymologic , Gingiva/enzymology , Humans , Immunologic Memory , Middle Aged , Normal Distribution , Statistics, Nonparametric , Up-Regulation
2.
Rev Gaucha Enferm ; 22(1): 69-82, 2001 Jan.
Article in Portuguese | MEDLINE | ID: mdl-11993107

ABSTRACT

This paper refers to teaching/learning in a subject named Fundaments of Human Care III--Care Module--at the Nursing School of the Universidade Federal do Rio Grande do Sul, under the vision of the undergraduate student. In 1996, the subject started at the fourth semester of the curriculum, constituted of its basic thematic, and in which the students learn about the genesis of human care process. The daily reports of the students during this module practice at the Pediatric Oncology Unit (POU) of a University Hospital, in Porto Alegre, RS, were submitted to phenomenological analysis, based on Merleau-Ponty (Martins, 1992). From this analysis emerged the significance expressed by the student of the experiences on the POU; the relation between teaching-practice; theoretical basis and care.


Subject(s)
Education, Nursing , Nursing Care/standards , Humans
3.
J Chromatogr ; 308: 229-39, 1984 Jun 08.
Article in English | MEDLINE | ID: mdl-6746816

ABSTRACT

A method for the measurement in plasma, blood and urine of progabide, its main acid metabolite, and the corresponding benzophenone is described. This assay allows the determination of progabide and its acid metabolite for therapeutic drug monitoring, and with a minimum detectable concentration of 1-10 ng/ml for progabide and its acid metabolite, it is sensitive enough for pharmacokinetic studies. Progabide and its metabolites are extracted from biological samples with toluene at pH 4.5. Following reduction of the imine bond with sodium borohydride, the reduced drugs are back-extracted into an aqueous phase at acid pH and reextracted by diethyl ether at alkaline pH. Progabide, its acid metabolite and the benzophenone are separated by high-performance liquid chromatography using a 3-micron ODS column with a quaternary solvent mixture of methanol-acetonitrile-phosphate buffer (0.033 M, pH 5.5)-sodium chloride (1.5 M) (30:30:40:9, v/v), and detected electrochemically at a potential of +850 mV vs. an Ag/AgCl electrode. Antiepileptic drugs like carbamazepine, carbamazepine epoxide, phenytoin, valproic acid and ethosuximide do not interfere with the assay. Blood/plasma partition ratios of 0.69 and 0.55 for progabide and its acid metabolite, respectively, indicate that the former but not the latter is present in red blood cells.


Subject(s)
Anticonvulsants/blood , gamma-Aminobutyric Acid/analogs & derivatives , Anticonvulsants/urine , Chromatography, Gas , Chromatography, High Pressure Liquid/methods , Drug Stability , Electrochemistry , Humans , Hydrogen-Ion Concentration , Kinetics , Oxidation-Reduction , Solubility , Temperature , gamma-Aminobutyric Acid/blood , gamma-Aminobutyric Acid/metabolism , gamma-Aminobutyric Acid/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...